Therapeutic Variables in Cataract Surgery

This study has been completed.

Sponsor:

Information provided by:

Innovative Medical

ClinicalTrials.gov Identifier:

NCT00407017

First received: November 30, 2006

Last updated: August 17, 2007

Last verified: August 2007

History of Changes

Purpose

The purpose of this study is to compare patient outcomes in following cataract surgery in patients randomized to one of two surgical kits.

Condition	Intervention	Phase
Cataract Surgery	Drug: Gatifloxacin Drug: Ketorolac LS Drug: Pred Forte Drug: Moxifloxacin Drug: Nepafenac Drug: EconoPred Plus	Phase 4


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double-Blind

Resource links provided by NLM:

MedlinePlus related topics: Cataract

U.S. FDA Resources

Further study details as provided by Innovative Medical:

Eligibility


Ages Eligible for Study:	Child, Adult, Senior
Sexes Eligible for Study:	All

Criteria

Inclusion Criteria:

Males or females scheduled to undergo cataract surgery
Patients can be receiving monofocal IOLs only
Likely to complete all study visits and able to provide informed consent
Visual potential of 20/25 or better

Exclusion Criteria:

Known contraindications to any study medication or ingredients
Active ocular diseases or uncontrolled systemic disease
Active ocular allergies

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00407017

Locations


United States, Florida
The Center for Excellence in Eye Care
Miami, Florida, United States, 33176

Sponsors and Collaborators

Innovative Medical

Investigators


Principal Investigator:	William Trattler, MD	The Center For Excellence in Eye Care

More Information


ClinicalTrials.gov Identifier:	NCT00407017 History of Changes
Other Study ID Numbers:	5264-T
Study First Received:	November 30, 2006
Last Updated:	August 17, 2007

Additional relevant MeSH terms:


Cataract Lens Diseases Eye Diseases Moxifloxacin Gatifloxacin Methylprednisolone Hemisuccinate Prednisolone Ketorolac Nepafenac Prednisolone acetate Methylprednisolone acetate Methylprednisolone Prednisolone hemisuccinate Prednisolone phosphate Anti-Bacterial Agents	Anti-Infective Agents Topoisomerase II Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic Agents Cyclooxygenase Inhibitors

ClinicalTrials.gov processed this record on July 19, 2017

To Top